Samsung Biologics Co Ltd, the biopharmaceutical contract manufacturing affiliate of Samsung Group, is expected to apply on August 11 for stock exchange approval of what is set to be South Korea’s biggest IPO this year, two bourse officials said.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
